Cite
A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma.
MLA
Makino, Tomoki, et al. “A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of S-588410, a Five-Peptide Cancer Vaccine as an Adjuvant Therapy after Curative Resection in Patients with Esophageal Squamous Cell Carcinoma.” Esophagus, vol. 21, no. 4, Oct. 2024, pp. 447–55. EBSCOhost, https://doi.org/10.1007/s10388-024-01072-w.
APA
Makino, T., Miyata, H., Yasuda, T., Kitagawa, Y., Muro, K., Park, J.-H., Hikichi, T., Hasegawa, T., Igarashi, K., Iguchi, M., Masaoka, Y., Yano, M., & Doki, Y. (2024). A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus, 21(4), 447–455. https://doi.org/10.1007/s10388-024-01072-w
Chicago
Makino, Tomoki, Hiroshi Miyata, Takushi Yasuda, Yuko Kitagawa, Kei Muro, Jae-Hyun Park, Tetsuro Hikichi, et al. 2024. “A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of S-588410, a Five-Peptide Cancer Vaccine as an Adjuvant Therapy after Curative Resection in Patients with Esophageal Squamous Cell Carcinoma.” Esophagus 21 (4): 447–55. doi:10.1007/s10388-024-01072-w.